{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-25-031973","form_type":"8-K","ticker":"CNTA","cik":"0001847903","company_name":"Centessa Pharmaceuticals plc","filed_at":"2025-02-21T23:59:59+00:00","discovered_at":"2026-05-14T18:03:05.271694+00:00","generated_at":"2026-05-26T07:11:28.569583+00:00","sec_items":["1.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Centessa licenses LockBody platform to Genmab; $15M upfront, up to $230M per product milestones","bullets":["Upfront payment of $15M from Genmab; option fees up to $15M for up to three undisclosed targets.","Eligible for ~$230M in development, regulatory, and sales milestones per product plus tiered mid-single-digit royalties.","Genmab to lead all R&D; may combine LockBody technology with Genmab's proprietary antibodies.","LockBody platform enables conditional activation of cell killing in diseased tissue to improve therapeutic index.","Multi-year research period; Genmab can terminate for convenience or on a target-by-target basis."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-25-031973","json":"https://secwatch.observer/filing/0001193125-25-031973.json","markdown":"https://secwatch.observer/filing/0001193125-25-031973.md","text":"https://secwatch.observer/filing/0001193125-25-031973.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1847903/000119312525031973/0001193125-25-031973-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1847903/000119312525031973/d894992d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-26T07:11:28.569583+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}